Critical Outcome Technologies Inc.  

(Public, CVE:COT)   Watch this stock  
Find more results for COT
0.000 (0.00%)
Oct 24 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.55 - 0.57
52 week 0.21 - 0.90
Open 0.56
Vol / Avg. 156,800.00/135,794.00
Mkt cap 83.32M
P/E     -
Div/yield     -
EPS -0.05
Shares 148.73M
Beta 0.21
Inst. own     -
Dec 14, 2016
Q2 2017 Critical Outcome Technologies Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 29, 2016
Q1 2017 Critical Outcome Technologies Inc Earnings Release
Aug 3, 2016
Q4 2016 Critical Outcome Technologies Inc Earnings Release

Key stats and ratios

Q3 (Jul '16) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -129.28% -95.10%
Return on average equity -255.74% -180.78%
Employees 10 -
CDP Score - -


700 Collip Cir Suite 213
+1-519-8585157 (Phone)
+1-519-8585179 (Fax)

Website links


Critical Outcome Technologies Inc. (COTI) is a clinical-stage biopharmaceutical company. The Company is engaged in drug discovery and development. The Company uses machine learning to develop targeted therapies thereby managing the timeline and cost of getting new drug therapies to market. The Company's artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds with a high probability of being developed from disease specific drug discovery through chemical optimization and preclinical testing. The CHEMSAS platform technology is designed for small molecules, and as a drug candidate discovery engine can be applied to any disease target with information for the target of interest. The Company's initial focus is in advancing the treatment of cancer with the Company's lead compound, COTI-2, having a p53-dependent mechanism of action demonstrating selective and potent anti- cancer activity.

Officers and directors

John C. Drake Independent Chairman of the Board
Alison Silva President, Director
Wayne R. Danter M.D. Chief Executive Officer, Chief Scientific Officer, Director
Gene Kelly Chief Financial Officer
Bharatt M. Chowrira Ph.D., J.D. Director
Age: 51
Douglas S. Alexander Independent Director
Bruno C. Maruzzo Independent Director
Age: 61
Dave Sanderson Independent Director